The National Agency for Food and Drug Administration and Control (NAFDAC) has officially blacklisted Onifam Laboratories Ltd. following a comprehensive investigation that uncovered severe regulatory misrepresentations and various violations capable of compromising the health of the Nigerian public. This decisive action, announced by the Director-General of NAFDAC, Professor Mojisola Adeyeye, underscores the agency’s intensified efforts to sanitize the nation’s pharmaceutical supply chain and ensure that only products meeting stringent safety and quality standards reach consumers. Speaking during a high-level news briefing held on Monday at the agency’s Investigation and Enforcement Directorate in Apapa, Lagos, Professor Adeyeye detailed the systemic failures and deliberate circumventions that led to the company’s expulsion from the regulated industry.

The Director-General, who was represented at the briefing by Martins Iluyomade, the Director of Investigation and Enforcement, explained that the blacklisting was not a sudden measure but the culmination of an exhaustive probe into the company’s operational activities. The investigation revealed that Onifam Laboratories Ltd. had engaged in the improper use of regulatory approvals and certificates, effectively undermining the traceability and accountability mechanisms that are the bedrock of Nigeria’s medicine regulatory system. According to the agency, the company’s actions constituted a direct violation of the NAFDAC Act, Cap. N1 LFN 2004, as well as the Food, Drug and Related Products Act, Cap. F33 LFN 2004. Furthermore, the company was found to be in breach of the Drug and Related Products Registration Regulations of 2021 and other applicable guidelines designed to safeguard the pharmaceutical market.

Detailed Findings of the Regulatory Investigation

The core of NAFDAC’s grievances against Onifam Laboratories Ltd. lies in what the agency describes as "regulatory misrepresentation." This term encompasses a range of deceptive practices, including the misuse of "Certificates of No Objection." In the pharmaceutical regulatory framework, a Certificate of No Objection is a critical document that allows for the importation or processing of specific items under strict conditions. NAFDAC’s investigation discovered that Onifam had been utilizing these approvals for purposes entirely outside their approved scope. This misuse allowed the company to bypass the rigorous oversight required for the importation, distribution, and marketing of regulated products.

Traceability, another pillar of pharmaceutical safety, was also severely compromised by the company’s activities. By circumventing established protocols, the company made it difficult, if not impossible, for the agency to track the movement of products from the point of manufacture or import to the final consumer. In the event of a product recall or a reported adverse drug reaction, such a lack of traceability could lead to catastrophic public health outcomes, as contaminated or substandard medicines could remain in circulation without the regulator’s ability to pinpoint their location.

The agency also highlighted the discovery of improper registration and licensing. It was revealed that Onifam Laboratories Ltd. had been involved in the assignment, marketing, and control of pharmaceutical products by entities that lacked the necessary documentation and legal standing. This "shadow" operation effectively created a parallel, unregulated channel for pharmaceutical products, posing a significant risk to the integrity of the national drug distribution system.

The Legal and Statutory Mandate for Blacklisting

The decision to blacklist Onifam Laboratories Ltd. is rooted in the statutory powers granted to NAFDAC. As the primary regulator of food, drugs, and chemicals in Nigeria, the agency is mandated to control the manufacture, importation, advertisement, and sale of regulated products. Professor Adeyeye emphasized that the blacklisting is an exercise of this mandate, intended to serve as both a punitive measure and a deterrent to other industry players who might consider cutting corners.

Under the current enforcement order, Onifam Laboratories Ltd. is prohibited from engaging in any pharmaceutical business regulated by NAFDAC until further notice. This ban extends to all entities associated with Onifam. These affected parties are barred from applying for, renewing, varying, or transferring any NAFDAC registration, license, permit, or certificate. Furthermore, they are prohibited from acting as manufacturers, importers, distributors, representatives, agents, consultants, or sponsors for any product that falls under NAFDAC’s jurisdiction.

The agency’s leadership made it clear that this blacklist would remain in force indefinitely, pending further directives from the management. NAFDAC has also reserved the right to pursue additional legal and administrative actions, which could include criminal prosecution of the individuals behind the company’s regulatory breaches.

Context: The Battle Against Substandard and Falsified Medicines in Nigeria

The blacklisting of Onifam Laboratories Ltd. comes at a time when NAFDAC is ramping up its "War Against Fake Drugs." Nigeria, like many developing economies, has long struggled with the influx of substandard and falsified (SF) medical products. According to data from the World Health Organization (WHO), a significant percentage of medicines in circulation in low- and middle-income countries are either substandard or falsified, leading to thousands of preventable deaths annually and fostering antimicrobial resistance.

In Nigeria, NAFDAC has implemented several technological and administrative interventions to combat this menace. These include the use of Mobile Authentication Service (MAS) via scratch codes, the deployment of Truscan devices for instant field testing of drug quality, and the recent push for full-scale "Track and Trace" technology using GS1 global standards. The actions of Onifam Laboratories Ltd. represent a direct assault on these technological advancements, as regulatory misrepresentation effectively blindsides the systems meant to ensure product authenticity.

The pharmaceutical industry is a high-stakes environment where the cost of regulatory failure is measured in human lives. By misusing approvals, companies like Onifam create a loophole where unverified products can enter the market under the guise of legitimacy. This not only puts patients at risk of treatment failure or poisoning but also erodes public confidence in the healthcare system and the "Made in Nigeria" pharmaceutical brand.

Timeline of Recent Enforcement Actions

The blacklisting of Onifam is part of a broader chronology of enforcement actions taken by NAFDAC over the past year.

• Early 2024: NAFDAC conducted nationwide raids on open drug markets, particularly in locations like Sabon Gari in Kano and Idumota in Lagos, seizing billions of Naira worth of unregistered and expired medicines.
• Mid-2024: The agency launched a specialized campaign urging Nigerians to scrutinize food and drug labels, highlighting the importance of NAFDAC registration numbers and expiry dates.
• Recent Months: There has been an increased focus on the "Certificate of No Objection" process, with the agency auditing several pharmaceutical firms to ensure compliance with the specific conditions attached to these permits.
• The Current Action: The formal announcement on Monday regarding Onifam Laboratories Ltd. serves as a climax to these efforts, signaling that even established entities are not immune to the highest level of sanctions if they violate public trust.

Broader Implications for the Pharmaceutical Sector

The blacklisting of a laboratory and its associated entities sends a powerful message to the Nigerian pharmaceutical industry. For legitimate manufacturers and importers, it reinforces the value of compliance and provides a more level playing field by removing actors who gain an unfair competitive advantage through illegal shortcuts. However, for the broader sector, it also highlights the increasing stringency of NAFDAC’s oversight.

Market analysts suggest that this move will likely lead to a "flight to quality," where distributors and retailers become more discerning about the companies they partner with. There is also the potential for an economic impact on the employees and stakeholders of the blacklisted firm; however, NAFDAC maintains that the economic survival of a non-compliant company cannot be prioritized over the lives of millions of Nigerians.

From a public health perspective, the removal of Onifam from the supply chain is a preemptive strike against the potential distribution of unsafe medicines. It emphasizes the agency’s shift from reactive enforcement to a more proactive, systemic approach where the integrity of the regulatory process itself is defended as a matter of national security.

NAFDAC’s Commitment to Public Health Safeguards

In her concluding remarks at the briefing, Professor Adeyeye reiterated that NAFDAC’s primary loyalty is to the Nigerian consumer. She stated that the agency would continue to preserve the integrity of the country’s pharmaceutical regulatory system at all costs. The "zero-tolerance" policy for regulatory misconduct is intended to ensure that Nigeria is not used as a dumping ground for inferior products and that local manufacturing adheres to Global Best Practices (GBP).

The agency has also called on the public and healthcare professionals to remain vigilant. Pharmacists, doctors, and patients are encouraged to report any suspicious pharmaceutical products or companies to NAFDAC through its various whistleblowing channels. The agency’s "See Something, Say Something" initiative remains a vital component of its intelligence-gathering apparatus.

As the blacklist remains in force, the pharmaceutical community will be watching closely to see how Onifam Laboratories Ltd. responds and whether this action leads to further revelations involving other entities. For now, the message from the Apapa briefing is clear: the era of circumventing NAFDAC’s regulatory controls without consequence is over. The agency stands firm in its resolve to protect the health of the nation, ensuring that the medicines available in Nigeria are safe, effective, and of the highest quality.